Omeros (FRA:3O8) Institutional Ownership : 21.14% (As of May. 15, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Omeros's institutional ownership is 21.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Omeros's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Omeros's Float Percentage Of Total Shares Outstanding is 95.64%.

Omeros Institutional Ownership Historical Data

The historical data trend for Omeros's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Institutional Ownership Chart

Omeros Historical Data

The historical data trend for Omeros can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	21.76	21.71	21.99	21.92	18.85	19.01	19.77	19.91	19.92	21.14

Omeros Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines